

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to "Commissioner for Patents, Washington, DC 20231."

Attorney Docket No. 9500-0001


"Express Mail" Mailing Label No.: EL910310837US

Date of Deposit: August 1, 2001

Sam Pen

Printed Name of Person Mailing Paper or Fee

Signature of Person Mailing Paper or Fee



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Leonard W. KAPLAN et al.

Serial No.: Nonprovisional of Provisional

Serial No. 60/223,541

Group Art Unit: Unassigned

Filing Date: Concurrently herewith

Examiner: Unassigned

Title: FORMULATIONS OF MOMETASONE AND A BRONCHODILATOR FOR
PULMONARY ADMINISTRATION

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Box Patent Application
Washington, DC 20231

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. PATENT DOCUMENTS		
PATENT NO.	ISSUE DATE	PATENTEE
4,472,393	9/18/84	Shapiro
5,126,123	6/30/92	Johnson
5,688,782	11/18/97	Neale et al.

U.S. PATENT DOCUMENTS		
PATENT NO.	ISSUE DATE	PATENTEE
5,955,439	9/21/99	Green
6,030,604	2/29/00	Trofast
6,057,307	5/2/00	Sequeira et al.

OTHER DOCUMENTS
Bernstein et al. (1999), "Dose-Ranging Study of a New Steroid for Asthma: Mometasone Furoate Dry Powder Inhaler," <i>Respiratory Medicine</i> 93(9):603-612.
Chapman et al. (1999), "Salmeterol and Fluticasone Propionate (50/250 µg) Administered via Combination Diskus Inhaler: As Effective as When Given via Separate Diskus Inhalers," <i>Can. Respir. J.</i> 6(1):45-51.
Chapman et al. (1998), "Anti-Inflammatory Activity of Inhaled Mometasone Furoate in Allergic Mice," <i>Arzneimittelforschung</i> 48:384-391.
Kelson et al. (1999), "Salmeterol Added to Inhaled Corticosteroid Therapy Is Superior to Doubling the Dose of Inhaled Corticosteroids: A Randomized Clinical Trial," <i>Journal of Asthma</i> 36(8):703-715.
Lumry (1999), "A Review of the Preclinical and Clinical Data of Newer Intranasal Steroids Used in the Treatment of Allergic Rhinitis," <i>J. Allergy Clin. Immunol.</i> 104(4 Pt. 1):S150-S158.
Nayak et al. (2000), "Once-Daily Mometasone Furoate Dry Powder Inhaler in the Treatment of Patients with Persistent Asthma," <i>Annals of Allergy, Asthma, & Immunology</i> 84:417-424.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants are filing this Disclosure Statement at the time of filing the application, no fee is required.

Respectfully submitted,

8/1/01
Date

By: Dianne E. Reed
Dianne E. Reed
Registration No. 31,292

REED & ASSOCIATES
800 Menlo Avenue, Suite 210
Menlo Park, California 94025
(650) 330-0900 Telephone
(650) 330-0980 Facsimile